7c8246a6-3f2c-42e1-b09f-959cfbf7fd5a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.480
- INTERFERON_ALPHA_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.420
- GLYCOLYSIS+0.390
- ALLOGRAFT_REJECTION+0.350
- E2F_TARGETS+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- INFLAMMATORY_RESPONSE+0.280
- FATTY_ACID_METABOLISM+0.240
- HYPOXIA+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- UV_RESPONSE_DN-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
- ANGIOGENESIS-0.310
- MYOGENESIS-0.290
- TGF_BETA_SIGNALING-0.290
- APICAL_JUNCTION-0.190
- PROTEIN_SECRETION-0.190
- HEDGEHOG_SIGNALING-0.150
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.824 |
| 2 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.824 |
| 3 | 213f702a-56fd-4ab0-940c-a71e4e01b6f8 | — | — | 0.822 |
| 4 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.822 |
| 5 | 20100231.Her2HRpos | — | C | 0.821 |
| 6 | fe1628d5-92d9-4e5c-a441-531b699014f1 | — | — | 0.812 |
| 7 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.808 |
| 8 | TCGA-BH-A0C0-01A-21R-A056-07 | — | C | 0.803 |
| 9 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.799 |
| 10 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.390 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |